CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $20.25M, above the global median of $18.69M
- PositionProfit margin is 37.6%, higher than 95% of its Biotechnology peers (median -63.8%)
- Interpretations10 currently firing — 10
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
5.38%Above 5Y avg (1.37%)
Annual Rate
CNY 0.64Paid annual
Payout Ratio
94.1%High
Payback Period
17.4 yr
Last Ex-Dividend
May 26, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.53BCNY829.22M · vs all stocks (USD)
Trailing P/E
17.32xvs Biotechnology peers
Revenue (TTM)
836.28MCNY125.33M · vs all stocks (USD)
Profit Margin
37.61%vs Biotechnology peers
Beta
0.3520xvs all stocks
52-Week Change
-30.01%vs all stocks
Market Capitalization
5.53BCNY829.22M · vs all stocks (USD)
Enterprise Value
2.85BCNY426.76M · vs all stocks (USD)
Trailing P/E
17.32xvs Biotechnology peers
Forward P/E
11.78xvs Biotechnology peers
Price to Sales (TTM)
6.57xvs Biotechnology peers
Price to Book (MRQ)
1.34xvs Biotechnology peers
Enterprise to Revenue
3.40xvs Biotechnology peers
Enterprise to EBITDA
7.83xvs Biotechnology peers
Gross Margin
52.30%vs Biotechnology peers
Profit Margin
37.61%vs Biotechnology peers
Operating Margin
-1.00%vs Biotechnology peers
Return on Assets (TTM)
3.38%vs Biotechnology peers
Return on Equity (TTM)
7.73%vs Biotechnology peers
Revenue (TTM)
836.28MCNY125.33M · vs all stocks (USD)
Revenue per Share (TTM)
1.81CNYUpdated Oct 24, 2026Quarterly Revenue Growth
-39.60%vs Biotechnology peers
Gross Profit (TTM)
506.73MCNY75.94M · vs all stocks (USD)
EBITDA (TTM)
355.54MCNY53.29M · vs all stocks (USD)
Net Income (TTM)
314.55MCNY47.14M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-67.30%vs Biotechnology peers
Operating Cash Flow (TTM)
410.07MCNY61.46M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
135.10MCNY20.25M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.6400CNYUpdated Oct 24, 2026Trailing Annual Dividend Yield
5.38%vs all stocks
5-Year Average Dividend Yield
1.37%vs all stocks
Payout Ratio
94.12%vs Biotechnology peers
Minority Interest (Equity)
397.45KCNYFY2025 · Dec 31, 2025Revenue
949.74MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
313.67MCNYFY2025 · Dec 31, 2025Gross Profit
636.07MCNYFY2025 · Dec 31, 2025Operating Income
388.23MCNY58.18M · vs all stocks (USD)
Pre-tax Income
481.54MCNYFY2025 · Dec 31, 2025Income Tax Expense
64.60MCNYFY2025 · Dec 31, 2025Net Income
416.94MCNYFY2025 · Dec 31, 2025EBIT
479.77MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
562.69MCNYFY2025 · Dec 31, 2025Research & Development
96.41MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
64.05MCNYFY2025 · Dec 31, 2025Other Operating Expenses
11.16MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
56.42MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
-1.77MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.9000CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.9000CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
465.25MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
465.25MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
416.94MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.78MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
397.05MCNYFY2025 · Dec 31, 2025Free Cash Flow
280.93MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
176.80MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
416.94MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-44.02MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
54.55MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-30.42MCNYFY2025 · Dec 31, 2025Capital Expenditures
-116.12MCNYFY2025 · Dec 31, 2025Net Acquisitions
-4.50MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.94BCNYFY2025 · Dec 31, 2025Sale of Investments
1.41BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-648.89MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-199.48MCNYFY2025 · Dec 31, 2025Other Financing Charges
15.21MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-184.27MCNYFY2025 · Dec 31, 2025Shares Outstanding
466.13MSharesUpdated Oct 24, 2026Float Shares
111.28MSharesUpdated Oct 24, 2026% Held by Insiders
74.78%vs all stocks
% Held by Institutions
0.77%vs all stocks
Total Cash (MRQ)
2.57BCNY385.70M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.60CNYUpdated Oct 24, 2026Total Debt (MRQ)
6.59MCNY987.21K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0016xvs Biotechnology peers
Current Ratio (MRQ)
7.82xvs Biotechnology peers
Book Value per Share (MRQ)
8.77CNYUpdated Oct 24, 2026Total Assets
4.79BCNY717.76M · vs all stocks (USD)
Total Current Assets
2.93BCNYFY2025 · Dec 31, 2025Total Liabilities
550.03MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.86BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
92.53MCNYFY2025 · Dec 31, 2025Total Current Liabilities
457.50MCNYFY2025 · Dec 31, 2025Cash
175.81MCNYFY2025 · Dec 31, 2025Cash Equivalents
990.44KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
176.80MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.54BCNYFY2025 · Dec 31, 2025Accounts Receivable
285.15MCNYFY2025 · Dec 31, 2025Inventory
144.27MCNYFY2025 · Dec 31, 2025Accounts Payable
111.32MCNYFY2025 · Dec 31, 2025Short-term Debt
1.61MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.12MCNYFY2025 · Dec 31, 2025Long-term Debt
5.07MCNYFY2025 · Dec 31, 2025Common Stock (Book)
466.13MCNYFY2025 · Dec 31, 2025Retained Earnings
2.37BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.24BCNY635.33M · vs all stocks (USD)
Treasury Stock
17.69MCNYFY2025 · Dec 31, 202552-Week Low
11.45CNYUpdated Oct 24, 202652-Week High
17.81CNYUpdated Oct 24, 202652-Week Change
-30.01%vs all stocks
Beta
0.3520xvs all stocks
50-Day MA
12.54CNYUpdated Oct 24, 2026200-Day MA
13.98CNYUpdated Oct 24, 2026Avg 10-Day Volume
1.10MSharesUpdated Oct 24, 2026Avg 30-Day Volume
1.11MSharesUpdated Oct 24, 2026Diluted EPS (TTM)
0.6800CNYUpdated Oct 24, 202610 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
How is this stock valued?
Down-Close Streak With Profitability
A run of down weeks on a company profitable three years running and funded by equity.
Reads
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Low RSI With Profitability And Equity Ratio
Recent weekly losses have outpaced gains, on three profitable years and heavy equity.
Reads
Near 52W Low With Profitability And FCF
Within 1% of its 52-week low, profitable three years, and capex takes less of its cash flow than at most of its peers.
Reads
Near All-Time Low With Profitability
Within 5% of its all-time low, profitable three years, and equity-funded.
Reads
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 37.6%, higher than 95% of its Biotechnology peers (median -63.8%)Significant
Profit margin: 0.38Industry median: -0.64Industry P95: 0.36Peers compared: 255
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 255
Financial Health
Altman Z-Score 7.88: safe zoneNotable
Altman Z-Score: 7.88
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $20.25M, above the global median of $18.69MNotable
Levered free cash flow (USD): 20,247,324.298Global Median: 18,689,872.41
Companies that share the same coordination system — how they create, deliver, or capture value.
Oxford Biomedica plc
Tier 1ProductionApproval-Gated PipelineFlowRule
Zhejiang International Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlow
Hainan Haiyao Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Esperion Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Wanbang Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Knight Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
BMC Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing SL Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventiva S.A.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jiudian Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Xinxiang Richful Lube Additive Co., Ltd.
8 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityLow RSI With Profitability And Equity RatioNear All-Time Low With ProfitabilityNear 52W Low With Profitability And FCFDown-Close Streak With ProfitabilityPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Jiangsu Tianmu Lake Tourism Co. Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedNear 52W Low With Profitability And FCFDown-Close Streak With ProfitabilityPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And EquityMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Chengdu RML Technology Co. Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesLow RSI With Profitability And Equity RatioNear All-Time Low With ProfitabilityCash-Flow Ratios ElevatedNear 52W Low With Profitability And FCFPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity